Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
UBS
Boehringer Ingelheim
AstraZeneca
Deloitte

Generated: May 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,902,744

« Back to Dashboard

Which drugs does patent 6,902,744 protect, and when does it expire?

Patent 6,902,744 protects BYETTA and is included in one NDA.

This patent has seventy-four patent family members in nineteen countries.

Summary for Patent: 6,902,744
Title: Exendin agonist formulations and methods of administration thereof
Abstract:Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Inventor(s): Kolterman; Orville G. (Poway, CA), Young; Andrew A. (La Jolla, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:09/889,330
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,902,744
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,902,744
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,902,744

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab BYETTA exenatide synthetic INJECTABLE;SUBCUTANEOUS 021773-001 Apr 28, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astrazeneca Ab BYETTA exenatide synthetic INJECTABLE;SUBCUTANEOUS 021773-002 Apr 28, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,902,744

PCT Information
PCT FiledJanuary 14, 2000PCT Application Number:PCT/US00/00902
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/41546

International Family Members for US Patent 6,902,744

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 275967 ➤ Try a Free Trial
Austria 299031 ➤ Try a Free Trial
Austria 347901 ➤ Try a Free Trial
Austria 460942 ➤ Try a Free Trial
Australia 2003239910 ➤ Try a Free Trial
Australia 2004202293 ➤ Try a Free Trial
Australia 2005200206 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Mallinckrodt
Teva
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.